Shamir Medical Center Reveals New Long-Term Results from Long COVID Study to Highlight Positive Impact on Symptoms Resulting from Hyperbaric Oxygen Therapy
Today, Aviv Clinics reveals results from the Sagol Center for Hyperbaric Medicine and Research at Shamir Medical Center and Tel Aviv University from a longitudinal long Coronavirus disease (COVID) study highlighting hyperbaric oxygen therapy (HBOT) as an effective treatment for those with long COVID…
IR-MED to Report New Clinical Efficacy Data for Detection of Pressure Injuries with its AI- Based PressureSafe™ Device at NPIAP 2024 Annual Conference on February 16
IR-MED Inc., (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive artificial intelligence (AI) driven spectrographic analysis technology platform to address significant healthcare needs, announced today that final data from a study conducted at two medical centers, Beit Rivka Hospital,…
Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA 
Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application for Onivyde® (irinotecan liposome injection) plus oxaliplatin, fluorouracil and leucovorin (NALIRIFOX) as a first-line treatment in adults living with…
Hemab Therapeutics Presents Positive Phase 1 Results for HMB-001 in Glanzmann Thrombasthenia at 2024 EAHAD Annual Congress
Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, today presented initial results from Phase 1 of its ongoing evaluation of HMB-001. A novel bispecific antibody, HMB-001 is in development as a prophylactic…
Healthcare Leaders Unite for Revolutionary Changes in Upcoming 2024 Budget
As the nation stands on the cusp of the Budget 2024 announcement, leading voices from the healthcare sector have shared their anticipations and aspirations. The sector, which has been at the forefront in the battle against recent health challenges, looks…
First Patient Dosed in Clinical Trial of YOLT-201 for the Treatment of Hereditary ATTR-CM
YolTech Therapeutics today announced that the first patient has been dosed with YOLT-201, the company’s first in vivo genome editing candidate being developed as a single dose, potentially curative therapy for hereditary transthyretin amyloidosis with cardiomyopathy (ATTR-CM). The study by YolTech is…
Mindfulness Nonprofit Kula for Karma Fights the Mental Health Crisis
Kula for Karma, a 501(c)3 providing mindfulness-based mental health care to people experiencing trauma, addiction, and mental health issues, is innovating in response to the national mental health emergency precipitated by the pandemic. Founder Geri Topfer, a pioneer of teaching life-changing mindfulness skills to…
SK bioscience and Hilleman Laboratories Announce Joint Development of Second-Generation Zaire Ebola Virus Vaccine
SK bioscience, an innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced that the company has entered into a development licensing agreement with Hilleman Laboratories, a vaccines and biologics research and development organization committed…
Agilus Diagnostics publishes data study ahead of World Diabetes Day 2023
India has emerged as the diabetes capital of the world with incidence steadily on the rise over the last three decades. The prevalence of diabetes in India stood at 8.9% in 2019 with more than 77 million people with diabetes….
MVR-T3011 IV, Global First Intravenous Oncolytic Product, Successfully Concludes Phase I Clinical Study in the U.S. with Outstanding Safety Results
On November 9, 2023, ImmVira announced the successful completion of Phase I clinical study conducted on late-stage patients with various tumor types for our intravenous oncolytic product, MVR-T3011 IV, in the United States. This milestone was marked by the product’s exceptional safety results…
